Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value
Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study
Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
RealMed Launches New Website
Align Technology to Announce Second Quarter Fiscal 2009 Results on July 23, 2009
TeamHealth Recognized by National Quality Agency
Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content. Terms and conditions, including restrictions on redistribution, apply. Copyright © 1996-2009 PR Newswire Association LLC. All Rights Reserved. A United Business Media company.